[Altered urinary calcium excretion in prostate cancer patients subjected to androgen deprivation. Preliminary pilot study results.] / Alteración de la excreción urinaria de calcio en pacientes sometidos a deprivación androgénica por cáncer de próstata. Resultados preliminares de un estudio piloto.

OBJECTIVES: Androgen deprivation therapy (ADT) in prostate cancer is associated with the appearance of different adverse effects. Among these effects, notable ones that may affect metabolism are osteoporosis and metabolic syndrome. The aim of this study is to analyse lithogenic risk markers three months after initiating treatment with LHRH analogue. METHODS: Pilot study encompassing 15 prostate cancer patients who were candidates for ADT, which they received in the form of quarterly doses of goserelin 10.8 mg. A blood and urine analyses for lithogenic risk, bone and metabolic markers were carried out, as was a study of metabolic syndrome criteria. Statistical analysis was performed with SPSS 17.0, taking P≤.05 to be statistically significant. RESULTS: Patients included in the study had a mean age of 72.46 ± 6.61 years. We observed a significant increase in the percentage of metabolic syndrome (20% versus 46.7%; P<.05) and insulin resistance index (1.87 versus 2.96; P=.01) at 3 months treatment. There was a notable increase in bone remodelling markers and significant increases in 24 h urinary calcium values (9.46 versus 14.57 mg/dl; P=.008), 24 h urinary calcium excretion index (0.10 versus 0.13 mg/dl GF [glomerular filtration]; P=.01) and the fasting calcium/ creatinine ratio (0.107 versus 0.195; P=.007), without any changes to other lithogenous risk markers. CONCLUSIONS: Androgen deprivation therapy can lead to the short-term appearance, primarily when fasting, of hypercalciuria in prostate cancer patients, possibly in association with bone metabolism.

Alteración de la excreción urinaria de calcio en pacientes sometidos a deprivación androgénica por cáncer de próstata. Resultados preliminares de un estudio piloto / Altered urinary calcium excretion in prostate cancer patients subjected to androgen deprivation. Preliminary pilot study results

OBJETIVOS: La terapia de deprivación androgénica en el cáncer de próstata se relaciona con la aparición de diferentes efectos adversos. En el ámbito metabólico destacan la aparición de osteoporosis y síndrome metabólico. El objetivo de este estudio es analizar los marcadores de riesgo litógeno a los 3 meses de haber iniciado tratamiento con análogo LHRH. MÉTODOS: Estudio piloto que incluye a 15 pacientes con cáncer de próstata subsidiarios de tratamiento con deprivación androgénica que se realiza con goserelina 10,8 mg trimestral. Se realiza estudio en sangre y orina de marcadores de riesgo litógeno, marcadores óseos y metabólicos, así como estudio de criterios de síndrome metabólico. Análisis estadístico con programa SPSS 17.0, considerando p≤0,05 como significación estadística. RESULTADOS: La edad media de los pacientes incluidos fue de 72,46 ± 6,61 años. Se observó un aumento significativo del porcentaje de síndrome metabólico a los 3 meses de tratamiento (20% versus 46,7%; p < 0,05), así como del índice de resistencia a la insulina (1,87 versus 2,96; p = 0,01). Destaca un aumento de los marcadores de remodelado óseo, así como un aumento significativo de la calciuria (9,46 versus 14,57 mg/dl; p = 0,008), del índice de excreción urinario de calcio (0,10 versus 0,13 mg/dl FG; p = 0,01) y del cociente calcio/creatinina de ayunas (0,107 versus 0,195; p = 0,007), sin modificaciones en otros marcadores de riesgo litógeno. CONCLUSIÓN: La terapia de deprivación androgénica puede inducir a corto plazo incremento de la calciuria, fundamentalmente de ayunas, en este tipo de pacientes en posible relación con alteración del metabolismo óseo

OBJECTIVES: Androgen deprivation therapy (ADT) in prostate cancer is associated with the appearance of different adverse effects. Among these effects, notable ones that may affect metabolism are osteoporosis and metabolic syndrome. The aim of this study is to analyse lithogenic risk markers three months after initiating treatment with LHRH analogue. METHODS: Pilot study encompassing 15 prostate cancer patients who were candidates for ADT, which they received in the form of quarterly doses of goserelin 10.8 mg. A blood and urine analyses for lithogenic risk, bone and metabolic markers were carried out, as was a study of metabolic syndrome criteria. Statistical analysis was performed with SPSS 17.0, taking P≤.05 to be statistically significant. RESULTS: Patients included in the study had a mean age of 72.46 ± 6.61 years. We observed a significant increase in the percentage of metabolic syndrome (20% versus 46.7%; P<.05) and insulin resistance index (1.87 versus 2.96; P=.01) at 3 months treatment. There was a notable increase in bone remodelling markers and significant increases in 24 h urinary calcium values (9.46 versus 14.57 mg/dl; P=.008), 24 h urinary calcium excretion index (0.10 versus 0.13 mg/dl GF [glomerular filtration]; P=.01) and the fasting calcium/ creatinine ratio (0.107 versus 0.195; P=.007), without any changes to other lithogenous risk markers. CONCLUSIONS: Androgen deprivation therapy can lead to the short-term appearance, primarily when fasting, of hypercalciuria in prostate cancer patients, possibly in association with bone metabolism

Risk of renal stone formation in patients treated with luteinising hormone-releasing hormone analogues for prostate cancer: importance of bone metabolism and urine calcium.

PURPOSE: To determine whether androgen blockade produces metabolic changes in urine and increases the risk of calculi after 1 year of treatment. MATERIALS AND METHODS: The study included 38 patients, from the period April 2015 to June 2016, diagnosed with locally advanced prostate cancer or lymph node metastasis, and with an indication of androgen blockade. Androgen blockade was started with luteinising hormone-releasing hormone (LHRH) analogues, and a blood specimen, a fasting urine and 24-h urine were collected at the time of inclusion, and then at 1 year of follow-up. A study was performed at baseline and at 1 year with imaging tests. An analysis of the variables was performed with a p ≤ 0.05 considered as statistically significant. RESULTS: The mean age of the patients included in the study was 72.26 ± 6.75 years. As regards the biochemistry parameters, an increase in osteocalcin (from 16.28 ± 9.48 to 25.56 ± 12.09 ng/ml; p = 0.001) and an increase in ß-crosslaps (from 0.419 ± 0.177 to 0.743 ± 0.268 ng/ml; p = 0.0001) were observed. In the urinary parameters, a significant increase was observed in the fasting calcium/creatinine ratio (from 0.08 ± 0.06 to 0.13 ± 0.06; p = 0.002) and in the 24-h calcium renal excretion (from 117.69 ± 66.92 to 169.42 ± 107.18 mg; p = 0.0001). Calculi formation was observed in 12 of the 38 patients included (31.6%), with a mean size of 3.33 ± 1.31 mm. CONCLUSION: Treatment with LHRH analogues, as well as increasing the appearance of metabolic syndrome and speeding up the loss bone mineral density, causes an increase in fasting urine calcium.

Deprivación androgénica en cáncer de próstata y riesgo de aparición de litiasis renal. Resultados de un estudio de casos y controles / Androgen deprivation therapy in prostate cancer and risk of developing renal calculi: Results of a case-control study

Antecedentes y objetivo: El tratamiento de privación androgénica en el cáncer de próstata se asocia a la aparición de diferentes efectos adversos, entre los que se encuentran la osteoporosis y el síndrome metabólico. Ambos están relacionados con la aparición de nefrolitiasis. El objetivo de este estudio es analizar la aparición de nefrolitiasis en pacientes sometidos a este tratamiento con análogos LHRH. Pacientes y métodos: Estudio de casos y controles en el que se incluyeron un total de 85 pacientes divididos en 2 grupos: el grupo 1 estaba formado por 41 pacientes con tratamiento de privación androgénica y el grupo 2 por 44 pacientes sin tratamiento de privación androgénica. Resultados: En el grupo 1 se produjo litiasis de nueva aparición en 12 casos (29,3%) frente a 2 casos en el grupo 2 (4,5%) (p = 0,0001), a los 4,4 años de comenzar el tratamiento de privación androgénica. La odds ratio estimada fue de 8,69 (IC al 95% 1,81-41,76). Conclusión: Parece existir relación entre el tratamiento con análogos LHRH y la litiasis; no obstante, son precisos estudios prospectivos a largo plazo con control metabólico para poder establecer las causas que expliquen la aparición de este fenómeno (AU)

Background and objective: Androgenic deprivation therapy in prostate cancer is associated with the onset of different adverse effects, including osteoporosis and metabolic syndrome. Both are related to the onset of nephrolithiasis. The objective of this article is to study the incidence of renal stones in patients undergoing androgen deprivation therapy with LHRH analogue. Patients and methods: Case-control study including a total of 85 patients divided into 2 groups: group 1, with 41 patients on androgen deprivation therapy, and group 2, with 44 patients not receiving androgen deprivation therapy. Results: New-onset lithiasis was observed in 12 cases (29.3%) in group 1 compared to 2 cases (4.5%) in group 2 (P = .0001), 4.4 years after starting the androgen deprivation therapy. The estimated odds ratio was 8.69 (95% CI 1.81-41.76). Conclusion: The incidence of renal stones could be increased in patients receiving treatment with analogue LHRH. However, long-term prospective studies with a metabolic control are required to be able to establish the causes explaining the development of this phenomenon in patients undergoing treatment with androgen deprivation therapy (AU)

Androgen deprivation therapy in prostate cancer and risk of developing renal calculi: Results of a case-control study. / Deprivación androgénica en cáncer de próstata y riesgo de aparición de litiasis renal. Resultados de un estudio de casos y controles.

BACKGROUND AND OBJECTIVE: Androgenic deprivation therapy in prostate cancer is associated with the onset of different adverse effects, including osteoporosis and metabolic syndrome. Both are related to the onset of nephrolithiasis. The objective of this article is to study the incidence of renal stones in patients undergoing androgen deprivation therapy with LHRH analogue. PATIENTS AND METHODS: Case-control study including a total of 85 patients divided into 2 groups: group 1, with 41 patients on androgen deprivation therapy, and group 2, with 44 patients not receiving androgen deprivation therapy. RESULTS: New-onset lithiasis was observed in 12 cases (29.3%) in group 1 compared to 2 cases (4.5%) in group 2 (P=.0001), 4.4 years after starting the androgen deprivation therapy. The estimated odds ratio was 8.69 (95% CI 1.81-41.76). CONCLUSION: The incidence of renal stones could be increased in patients receiving treatment with analogue LHRH. However, long-term prospective studies with a metabolic control are required to be able to establish the causes explaining the development of this phenomenon in patients undergoing treatment with androgen deprivation therapy.

Estudio caso-control en hombres con liquen escleroso y atrófico genital / Case control study in men with sclerosus and atrophic genital lichen

Objetivo. Comparar los datos epidemiológicos de una muestra de pacientes con liquen escleroso genital versus un grupo control sin liquen escleroso genital. Material y métodos. Estudio caso-control que incluye 50 pacientes divididos en 2 grupos; grupo 1: 30 pacientes con liquen escleroatrófico genital y grupo 2: 20 pacientes sin liquen escleroatrófico. Se han estudiado variables clínicas, analíticas, antecedentes personales y hábitos de vida. El análisis estadístico se ha llevado a cabo mediante el programa SPSS 20.0, siendo la significación estadística p≤0,05. Resultados. La edad media de los pacientes del grupo 1 fue de 54,7años versus 52,5años en el grupo 2, sin que se observaran diferencias estadísticamente significativas. La principal diferencia observada entre los pacientes del grupo 1 y los del grupo 2 fue el índice de masa corporal, que fue más elevado en el grupo 1, 28,4kg/m2, con respecto al grupo 2, 23,4kg/m2 (p=0,0001), y el estado civil. No se observó una mayor prevalencia significativa en enfermedades autoinmunes en el grupo 1 respecto al grupo 2. Conclusión. Los pacientes con liquen escleroatrófico genital parecen tener mayor índice de masa corporal que los pacientes sin liquen, sin que exista una clara asociación con enfermedades autoinmunes, según los resultados de nuestro estudio (AU)

Objective. To compare epidemiologic dates in patients with sclerosus genital lichen versus control group without sclerosus genital lichen. Material and methods. Case-control study including 50 patients divided into 2 groups: Group 1: 30 patients with sclerosus and atrophic genital lichen and group 2: 20 patients without lichen sclerosus. Study of clinical variables, laboratory, medical history and lifestyle. Statistical analysis with SPSS 20.0 software and statistical significance P≤.05. Results. The mean age of patients in group 1 was 54.7 years versus 52.5 years in group 2, no statistically significant differences were observed. The main difference observed between patients in group 1 and group 2 was the BMI, which was higher in group 1, 28.4kg/m2, compared to group 2, 23.4kg/m2 (P=.0001) and marital status. It has not been observed significantly higher prevalence in autoimmune diseases in group 1 compared with group 2. Conclusion. Patients with genital sclerosus and atrophic lichen seem to be more body mass index than patients without lichen, without a clear association with autoimmune diseases according to the results of our study (AU)

Estudio epidemiológico de los pacientes con liquen escleroatrófico genital. Resultados preliminares / Epidemiological study of patients with genital lichen sclerosus. Preliminary results

Introducción: El liquen escleroso y atrófico es una enfermedad crónica, inflamatoria, adquirida, que produce una pérdida de calidad de vida y aumento de la morbilidad. Las causas de la aparición del liquen son desconocidas y es importante estudiar la relación de esta enfermedad con diferentes entidades patológicas, hábitos de vida y factores demográficos. Objetivo: El objetivo de este estudio es presentar unos resultados preliminares de una pequeña casuística de pacientes con liquen escleroso y atrófico. Material y métodos: Presentamos 20 pacientes sometidos a circuncisión por liquen escleroso y atrófico confirmado histológicamente, en los que analizamos características clínicas, analíticas y demográficas para completar un perfil epidemiológico del paciente con esta enfermedad. Resultados: La media de edad de los pacientes estudiados fue de 54,8 años. Destaca que el 25% de los pacientes presenta una diabetes mellitus, el 50% hipercolesterolemia y el 75% sobrepeso. En términos globales el perfil lipídico y glúcídico está alterado en el 50% de los pacientes que presentan esta enfermedad. Los pacientes con liquen presentan en un porcentaje importante de casos alteraciones del meato uretral, por lo que es importante su exploración. Conclusión: Aunque es un estudio limitado por el número de pacientes, debemos tener en cuenta la posible asociación del liquen escleroso y atrófico con dislipidemia y otras enfermedades endocrino-metabólicas (AU)

Introduction: lichen sclerosus et atrophicus, or lichen sclerosus, is an acquired, chronic inflammatory disease, resulting in a loss of quality of life and increased morbidity. The causes of the appearance of lichen are unknown and it is important to study the relationship of this disease with different pathologies and lifestyle and demographic factors. Objective: the objective of this study was to obtain and present some preliminary results from a small series of patients with lichen sclerosus. Material and methods: we report 20 patients undergoing circumcision due to histologically confirmed lichen sclerosus, in whom we analysed demographic, clinical and analytical characteristics to complete an epidemiological profile of patients with this disease. Results: the mean patient age was 54.8 years. It is notable that 25% of patients had diabetes mellitus, 50%, hypercholesterolemia and 75% were overweight. Overall lipid and carbohydrate profile was altered in 50% of patients with this disease. Patients with lichen present, in a significant percentage of cases, alterations of the urethral meatus, so the physical examination is very important. Conclusion: although this study had a limited number of patients, we have to bear in mind the possible association of lichen sclerosus with dyslipidemia and other endocrine and metabolic diseases